(Q41127972)

27 September 2017

1 reference

title

Treatment algorithms in treatment-resistant depression (English)

1 reference

ORCID Public Data File 2021

27 September 2017

0 references

1 reference

author name string

Amsterdam JD

series ordinal

1

1 reference

PubMed ID

8827195

27 September 2017

Hornig-Rohan M

series ordinal

2

1 reference

27 September 2017

1 June 1996

1 reference

Psychiatric Clinics of North America

27 September 2017

1 reference

27 September 2017

19

1 reference

27 September 2017

371-386

1 reference

27 September 2017

2

1 reference

Fluoxetine efficacy in treatment resistant depression

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Lack of correlation with therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Fluoxetine in tricyclic refractory major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

The importance of Axis II in patients with major depression. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Potentiation of lithium by tryptophan in a patient with bipolar illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

The Comparative Antidepressant Value of L-Tryptophan and Imipramine With and Without Attempted Potentiation by Liothyronine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Adding a tricyclic antidepressant to a monoamine oxidase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Rapid response to the addition of lithium in iprindole-resistant unipolar depression: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Thyroid Hormone and Tricyclic Antidepressants in Resistant Depressions

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Hormonal Potentiation of Imipramine and ECT in Primary Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Response of depressive symptoms to nortriptyline, phenelzine and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Failure of T3 to potentiate tricyclic antidepressant response

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Potentiation of a monoamine oxidase inhibitor by tryptophan

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Clinical implications of imipramine plasma levels for depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Analysis of time to stabilization in the treatment of depression: biological and clinical correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Unrecognized physical illness prompting psychiatric admission: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Tranylcypromine versus imipramine in anergic bipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Treatment Received by Depressed Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Phenelzine v imipramine in atypical depression. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Rapid response to lithium in phenelzine non-responders

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. A cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

POTENTIATION OF MONOAMINE-OXIDASE INHIBITORS BY TRYPTOPHAN

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Enhancement of imipramine antidepressant activity by thyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Efficacy of lithium-tranylcypromine treatment in refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Monoamine oxidase inhibitors. A review of antidepressant effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Tricyclic nonresponders: phenomenology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Fluoxetine in refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

The TRH test and thyroid hormone in refractory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Towards Rational Therapy with Monoamine Oxidase Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Potentiation of Amitriptyline by Thyroid Hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Combined MAOI-tricyclic antidepressant treatment: a reevaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

Thyroid-Hormone Enhancement of Imipramine in Nonretarded Depressions

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970293-8

7 January 2021

10.1016/S0193-953X(05)70293-8

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8827195